Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Insider Jason R. Kelly Sells 98,562 Shares

Ginkgo Bioworks Holdings, Inc. (NYSE:DNAGet Rating) insider Jason R. Kelly sold 98,562 shares of Ginkgo Bioworks stock in a transaction on Friday, November 18th. The stock was sold at an average price of $2.17, for a total transaction of $213,879.54. Following the transaction, the insider now directly owns 20,623,653 shares of the company’s stock, valued at $44,753,327.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ginkgo Bioworks Price Performance

DNA stock opened at $1.98 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 11.67 and a current ratio of 11.71. The business has a 50-day moving average price of $2.71 and a 200 day moving average price of $2.82. Ginkgo Bioworks Holdings, Inc. has a 1-year low of $1.94 and a 1-year high of $12.48.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. BTIG Research decreased their target price on Ginkgo Bioworks to $4.00 in a research report on Thursday, November 17th. Morgan Stanley assumed coverage on Ginkgo Bioworks in a research report on Tuesday, October 4th. They set an “equal weight” rating and a $5.00 target price for the company. Finally, Raymond James decreased their target price on Ginkgo Bioworks from $10.50 to $6.00 and set an “outperform” rating for the company in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, Ginkgo Bioworks currently has an average rating of “Hold” and a consensus target price of $5.91.

Institutional Trading of Ginkgo Bioworks

Several institutional investors and hedge funds have recently made changes to their positions in the company. ARK Investment Management LLC raised its holdings in Ginkgo Bioworks by 45.2% in the third quarter. ARK Investment Management LLC now owns 126,818,856 shares of the company’s stock worth $395,675,000 after purchasing an additional 39,460,799 shares in the last quarter. Baillie Gifford & Co. raised its holdings in Ginkgo Bioworks by 22.4% in the second quarter. Baillie Gifford & Co. now owns 205,327,786 shares of the company’s stock worth $488,680,000 after purchasing an additional 37,575,106 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. bought a new position in Ginkgo Bioworks in the second quarter worth about $52,022,000. State Street Corp raised its holdings in Ginkgo Bioworks by 210.3% in the second quarter. State Street Corp now owns 12,411,855 shares of the company’s stock worth $29,540,000 after purchasing an additional 8,411,787 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. raised its holdings in Ginkgo Bioworks by 46.5% in the second quarter. Nikko Asset Management Americas Inc. now owns 21,858,173 shares of the company’s stock worth $52,678,000 after purchasing an additional 6,937,185 shares in the last quarter. 53.37% of the stock is currently owned by institutional investors.

About Ginkgo Bioworks

(Get Rating)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Recommended Stories

Insider Buying and Selling by Quarter for Ginkgo Bioworks (NYSE:DNA)

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.